The lateral septum is where the brain thinks about rewards
For generations, addiction has been understood as a failure of will, a loop of desire that refuses to close — but science has long suspected the answer lies deeper, in the architecture of the brain itself. Now, a class of drugs developed to manage blood sugar and body weight has begun revealing something unexpected: that GLP-1 agonists like Ozempic quiet not just hunger, but the broader machinery of craving, reducing consumption of alcohol, cocaine, opioids, and nicotine across multiple studies. The discovery points to a small, long-overlooked structure called the lateral septum — a crossroads where memory, place, time, and reward converge into the conscious experience of wanting. In learning how these drugs interrupt that process, researchers may have found the first genuine map to the place where desire becomes disorder.
- Drugs prescribed for diabetes and obesity are unexpectedly reducing patients' desire for alcohol, cocaine, opioids, amphetamines, and nicotine — effects no one designed them to produce.
- The discovery has thrown decades of addiction neuroscience into revision, as the brain regions long assumed to be central to reward cannot alone explain what these drugs are doing.
- Researchers have traced the mechanism to the lateral septum, a densely GLP-1-receptor-rich region that weaves together memory, spatial context, and learned reward into the vivid mental image that precedes craving.
- Laboratory work, including studies from the University of Otago, shows that activating GLP-1 receptors in the lateral septum directly suppresses consumption and dampens the neural signals that drive it.
- The field is now racing to understand whether these findings can be translated into targeted treatments for substance use disorders — not as behavioral patches, but as interventions at the precise point where craving is assembled.
When the brain encounters something it has learned to want — the smell of a drink, the memory of a high — it doesn't merely register the stimulus. It constructs a full experience: image, memory, feeling, anticipation. For most people, this system motivates ordinary survival and pleasure. For others, it becomes a loop that cannot close. Addiction, at its core, is that construction running without an off switch.
GLP-1 agonists like Ozempic and Wegovy were built to mimic a natural hormone that triggers insulin release and creates satiety. Developed for type 2 diabetes, they produced dramatic weight loss as a side effect. But researchers began noticing something stranger: patients were also drinking less, smoking less, and reporting reduced cravings for drugs. The medications appeared to be touching something deeper than appetite — the brain's reward system itself.
For years, neuroscientists looked to the ventral tegmental area and nucleus accumbens as the seat of reward and addiction. But these regions lack sufficient GLP-1 receptors to explain the effect. The answer lay upstream, in the lateral septum — a structure historically associated with emotional regulation, now understood as the brain's reward-context hub. It receives spatial and temporal information from the hippocampus, adds the layer of learned reward, and passes an integrated signal — where I am, when I am, what is good here — to the dopamine systems that make us pursue what we want.
Research has shown that activating GLP-1 receptors directly in the lateral septum reduces food and alcohol consumption in mice. Work from Robert Munn's lab at the University of Otago suggests the drugs dampen a specific pattern of neural activity in this region, impairing its ability to broadcast the craving signal to the rest of the brain.
What this redraws is not just a map of addiction, but a theory of desire itself. Craving is not a simple impulse — it is assembled from memory, place, time, and association, and the lateral septum is where that assembly happens. By acting there, GLP-1 drugs do not merely suppress appetite; they interrupt the construction of wanting at its source. The implications reach far beyond weight loss, pointing toward a new class of treatments for substance use disorders that address not behavior, but the neural moment where the thought of the thing first takes shape.
When you see a burger or smell beer, your brain doesn't just register the stimulus—it conjures an image, a memory, a feeling. That cascade of thought drives you toward the thing. For most people, this system works as intended, motivating the basic acts of survival and pleasure. But in others, the machinery misfires. The craving becomes consuming. The thought becomes compulsion. Addiction, in its essence, is this loop broken.
For decades, neuroscience has circled this problem without quite solving it. How does desire become disorder? What happens in the brain when the wanting never stops? The answers have remained elusive, locked somewhere in the architecture of neural tissue that researchers could map but not fully understand. Then something unexpected happened. A class of drugs designed to manage blood sugar and weight loss began showing effects that no one quite anticipated. GLP-1 agonists—medications like Ozempic and Wegovy—started reducing not just appetite for food, but appetite for alcohol, cocaine, amphetamines, opioids, and nicotine. The drugs were revealing something fundamental about how the brain organizes desire itself.
These medications work by mimicking a natural hormone called GLP-1, which triggers insulin release, slows digestion, and creates a sense of fullness. They were developed for type 2 diabetes, where they proved effective at controlling blood sugar. The weight loss came as a side effect—sometimes dramatic, approaching what bariatric surgery might achieve. But the reduction in substance use was something else entirely. It suggested the drugs were touching something deeper than appetite. They were touching the brain's reward system at a point that controlled not just eating, but craving itself.
For years, neuroscientists focused on two obvious candidates: the ventral tegmental area and the nucleus accumbens, regions that produce dopamine and have been studied for decades as the seat of reward. These seemed like the logical place where GLP-1 drugs would act. But they don't have enough GLP-1 receptors to explain the effect. The mechanism had to be elsewhere. The answer turned out to be upstream, in a structure called the lateral septum—a region historically associated with emotional regulation, but now understood as something far more central to how we think about rewards.
The lateral septum sits at a crossroads of neural information. It receives input from the hippocampus, the brain region responsible for forming long-term memories and for tracking where and when we are in space and time. The hippocampus contains place cells, neurons that fire based on our sense of location and temporal position. But the lateral septum does something remarkable with this information. It contains its own place cells, but these cells respond not just to location and time—they respond to rewards. They add a layer of meaning: what is good in this place, at this time. This integrated information—where I am, when I am, what is rewarding here—gets passed along to the dopamine-producing regions that make us feel good about the things we want.
Think of the lateral septum as the seat of conscious craving. It's where the brain thinks about rewards, where it builds the vivid mental image of the burger or the drink. And it is absolutely dense with GLP-1 receptors. Recent research has shown that when GLP-1 is activated directly in the lateral septum of mice, food consumption drops. Earlier this year, another study showed the same effect for alcohol. Work from Robert Munn's lab at the University of Otago has demonstrated that GLP-1 drugs reduce a specific type of neural activity in the lateral septum that may impair its ability to communicate effectively with other brain regions—essentially dampening the signal that drives consumption.
What emerges from this research is a new map of addiction. It's not simply that the brain wants something and pursues it. The wanting is constructed from layers of information: memory, context, location, time, and the learned association between place and reward. The lateral septum is the place where all of this comes together, where the brain assembles the thought that drives the behavior. By acting on this region, GLP-1 drugs don't just reduce appetite—they interrupt the very process by which craving is formed and communicated to the brain's reward machinery.
This discovery reshapes not just how we understand addiction, but how we might treat it. The implications extend far beyond weight loss. If GLP-1 agonists can reduce the consumption of alcohol, cocaine, amphetamines, opioids, and nicotine—if they can quiet the neural machinery of craving itself—then they represent a fundamentally new approach to substance use disorders. Not a band-aid on behavior, but an intervention at the point where desire is constructed. The lateral septum, long overlooked, has become the focus of addiction research. And the drugs meant to help people lose weight may have opened a door to understanding and treating the disorders of wanting that have resisted treatment for so long.
Citas Notables
The lateral septum is the brain region that lets us think about rewards and communicates with the machinery that produces dopamine to make us feel good about them— Robert Munn, University of Otago
La Conversación del Hearth Otra perspectiva de la historia
So these drugs were designed for diabetes, and they happen to reduce addiction. That seems like a lucky accident.
It is, in a way. But the accident only makes sense once you understand what the drugs are actually doing in the brain. They're not just suppressing appetite generally—they're acting on a very specific region that controls how we think about rewards.
The lateral septum. Why is that region so important if it's not one of the famous reward centers everyone studies?
Because it's the translator. The ventral tegmental area and nucleus accumbens produce the feeling of pleasure, but the lateral septum is where the brain decides what's worth pursuing in the first place. It takes information about where you are, when you are, what you've learned about rewards in that context, and it builds the craving.
So if you dampen activity in the lateral septum, you're not making rewards feel less good—you're making the brain less likely to think about them in the first place.
Exactly. You're interrupting the thought before it becomes a compulsion. The vivid mental image of the drink or the drug doesn't form as strongly, or doesn't communicate as effectively to the dopamine system.
That's different from how we usually think about addiction treatment. We usually think about willpower or substitution.
It is. This is targeting the neural machinery of wanting itself. And the fact that it works across so many different substances—alcohol, cocaine, opioids, nicotine—suggests it's not about the specific drug. It's about the fundamental process of craving.
What happens next? Do we start prescribing these drugs for addiction?
That's the question now. We have animal studies and some human data on alcohol. But we need careful clinical trials to understand safety, dosing, and whether the effect holds up in real addiction treatment. The mechanism is becoming clear, but the medicine is still being written.